Mylan v. Alora Pharmaceuticals: 8-Patent ISB Infringement Action Dismissed in 30 Days
Mylan filed suit against Alora Pharmaceuticals in Georgia’s Northern District asserting eight patents covering isosulfan blue injection, a lymphatic mapping agent. Within 30 days of filing, Mylan voluntarily dismissed all claims without prejudice under Rule 41(a)(1)(A)(i), leaving the door open for future enforcement.
Eight-patent ISB infringement action ends before defendant responds
On October 13, 2025, Mylan filed a patent infringement action against Alora Pharmaceuticals, LLC in the United States District Court for the Northern District of Georgia (Case No. 1:25-cv-05870), presided over by Judge Tiffany R. Johnson. The complaint asserted eight issued U.S. patents — US10752580B2, US10590071B2, US8969616B2, US7662992B2, US10464888B2, US10508080B2, US10626086B2, and US9353050B2 — all directed to isosulfan blue injection, a dye used in lymphatic mapping and sentinel lymph node biopsy procedures. Mylan was represented by Wilson Sonsini Goodrich & Rosati, LLP and Hill, Kertscher & Wharton, LLP.
On November 12, 2025 — just 30 days after filing — Mylan filed a voluntary notice of dismissal pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), dismissing all claims against Alora Pharmaceuticals without prejudice. Because no defendant answer or motion for summary judgment had been filed, Mylan was entitled to dismiss as of right without court approval. No costs or fees were ordered. The without-prejudice designation means Mylan retains the right to refile the same claims at a later date, subject to applicable statutes of limitations.
A 30-day lifespan — from filing to dismissal — is unusually short and suggests the litigation may have served a strategic purpose beyond merits adjudication, such as triggering a 30-month stay under Hatch-Waxman, opening settlement negotiations, or testing Alora’s litigation posture. The public record does not disclose whether any agreement was reached between the parties, and no substantive rulings were issued. What remains unknown is whether Mylan intends to refile, and whether Alora’s isosulfan blue product will face renewed enforcement action.
Filing to Voluntary dismissal in 30 days
30-day duration — resolved before any substantive motion practice, well below median district court patent case timelines
Voluntarily dismissed: what the Rule 41 filing means for both parties
Rule 41(a)(1)(A)(i): dismissal as of right, no court order required
Under Fed. R. Civ. P. 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order at any point before the defendant serves an answer or a motion for summary judgment. Mylan invoked this provision exactly, meaning the dismissal took effect automatically upon filing. No judicial approval was required and no merits determination was made. This is the least costly and most reversible exit mechanism available in federal civil litigation.
No merits ruling issuedWithout prejudice: the distinction that matters most here
A dismissal ‘without prejudice’ means the plaintiff is not barred from refiling the same claims. A dismissal ‘with prejudice’ would extinguish those claims permanently. Mylan’s notice expressly states ‘without prejudice,’ preserving its enforcement rights across all eight patents. The public record does not disclose any agreement between the parties, nor whether this dismissal followed any negotiation. Practitioners should note that re-filing would restart the litigation clock and potentially face different venue or standing arguments.
Enforcement rights preservedAlora Pharmaceuticals escapes this action — but exposure persists
Alora Pharmaceuticals faced no adverse judgment and incurred no recorded fee or cost award, having not yet filed an appearance or response before dismissal. However, because the dismissal is without prejudice, Alora cannot treat this case as a final resolution. All eight asserted patents remain in force and Mylan retains the right to refile. Alora’s isosulfan blue product continues to carry infringement exposure, and any FTO analysis should account for this patent portfolio.
Refile risk remains30-day dismissal cycle: strategic litigation or preliminary manoeuvre?
The pace of this case — filed and dismissed within 30 days — is consistent with strategic use of patent litigation in the pharmaceutical sector, including Hatch-Waxman 30-month stay mechanics, pre-litigation settlement leverage, or competitive signalling. With eight patents across a specialist injectable dye, the breadth of Mylan’s portfolio suggests a well-prepared enforcement posture. Competitors and ANDA filers in the isosulfan blue space should monitor this docket closely for any refiling.
Pharmaceutical IP strategyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Mylan | Individual | Generic pharmaceutical company — holder of US10752580B2 and 7 further ISB injection patentsSearch in Eureka ↗ |
| Defendant | Alora Pharmaceuticals, LLC | Company | Specialty pharmaceutical company commercialising isosulfan blue injection productsSearch in Eureka ↗ |
| Plaintiff counsel | Emily Shingle | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff counsel | Kristina Hanson | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff counsel | Mark A. Hayden | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas Halkowski | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff counsel | Steven G. Hill | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff counsel | Tung-On Kong | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff counsel | Wendy L. Devine | Attorney | Counsel for MylanSearch in Eureka ↗ |
| Plaintiff law firm | Hill, Kertscher & Wharton, LLP | Law Firm | Representing MylanSearch in Eureka ↗ |
| Plaintiff law firm | Wilson Sonsini Goodrich & Rosati, LLP | Law Firm | Representing MylanSearch in Eureka ↗ |
| Presiding judge | Judge Tiffany R. Johnson | Judge | Georgia Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) with precision, confirming no responsive pleading had been filed at the time of dismissal. The explicit ‘without prejudice’ designation is legally significant: it forecloses any res judicata or claim preclusion defence Alora might otherwise have raised in future proceedings. No judicial findings were made on infringement, validity, or claim construction across any of the eight asserted patents, meaning the substantive IP questions raised by this complaint remain entirely unresolved.
US10752580B2 and 7 further patents — isosulfan blue injection formulations
The eight asserted patents — US10752580B2, US10590071B2, US8969616B2, US7662992B2, US10464888B2, US10508080B2, US10626086B2, and US9353050B2 — collectively cover isosulfan blue (ISB) injection, a water-soluble dye used intraoperatively to visualise lymphatic vessels during sentinel lymph node biopsy procedures. The portfolio spans multiple patent families with application dates ranging across more than a decade, suggesting layered protection over the compound, its formulations, and manufacturing processes. The breadth of the family structure is consistent with a classic pharmaceutical lifecycle management strategy.
Isosulfan blue has a narrow but critical commercial niche in oncology surgery, particularly in breast cancer and melanoma staging procedures. A portfolio of eight patents covering this single injectable product creates significant barriers for generic or competing specialty pharma entrants. For Alora Pharmaceuticals, which appears to be commercialising an ISB injection product, each asserted patent represents a separate clearance hurdle. The oldest grants — US7662992B2 and US8969616B2 — are likely closest to expiry but may still be in force, while the more recent grants extend protection into the early 2030s based on typical 20-year patent terms from filing.
Should you run an FTO against Mylan’s isosulfan blue injection patent portfolio?
Any company developing, manufacturing, or commercialising isosulfan blue injection products — including ANDA filers, specialty pharma entrants, and contract manufacturers — should treat Mylan’s eight-patent ISB portfolio as a material FTO risk. This case confirms the portfolio is actively monitored and enforced. The without-prejudice dismissal means no claim has been extinguished, and the speed of filing suggests Mylan has enforcement infrastructure ready to redeploy. R&D and regulatory teams planning ISB product launches should commission FTO analysis before any ANDA submission or NDA filing.
PatSnap Eureka’s FTO Search Agent can map each of the eight asserted patents against your product’s formulation, manufacturing process, and route of administration, identifying claim-by-claim overlap and non-infringing design-around pathways. Eureka also tracks patent family expiry dates across all related applications, helping you model launch windows with precision. For this portfolio specifically, Eureka can flag any continuation or divisional applications that may not yet be publicly asserted but share priority with the patents named in this complaint.
Run a freedom-to-operate analysis on US10752580B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical injectable patent infringement cases in US district courts
Cases involving pharmaceutical injectable patent portfolios filed in the Northern District of Georgia and comparable federal district courts, including Hatch-Waxman disputes and specialty drug enforcement actions.
What this case signals for the pharmaceutical injectable IP landscape
A rapid voluntary dismissal across an eight-patent portfolio rarely signals weakness — it typically signals leverage, negotiation, or a strategic procedural objective.
Multi-patent assertions amplify settlement pressure in pharma litigation
Asserting eight patents in a single complaint dramatically raises the cost and complexity of defence. Even where a plaintiff voluntarily dismisses quickly, the threat of reinstatement across a broad portfolio can be sufficient to achieve commercial objectives without merits adjudication. IP teams defending against multi-patent complaints should assess portfolio vulnerabilities before the first responsive pleading deadline.
Without-prejudice dismissals extend uncertainty for generic and specialty pharma entrants
For companies seeking to commercialise competing pharmaceutical products, a without-prejudice dismissal provides no freedom-to-operate certainty. Alora and similarly situated defendants should treat the dismissed patents as live threats, conduct thorough FTO analysis, and consider whether inter partes review (IPR) petitions could neutralise key claims before any refile.
Mylan v Alora — key questions answered
Mylan asserted eight U.S. patents: US10752580B2, US10590071B2, US8969616B2, US7662992B2, US10464888B2, US10508080B2, US10626086B2, and US9353050B2. All patents relate to isosulfan blue injection, a lymphatic mapping dye used in sentinel lymph node biopsy procedures. The complaint was filed on October 13, 2025 in the Northern District of Georgia.
The public record does not disclose the reason for Mylan’s voluntary dismissal. The notice invoked Rule 41(a)(1)(A)(i), filed before Alora had served any answer or summary judgment motion. The without-prejudice designation preserves Mylan’s right to refile. The 30-day duration between filing and dismissal is consistent with strategic litigation objectives such as settlement negotiation, Hatch-Waxman stay mechanics, or competitive signalling — but no agreement is on record.
No. A without-prejudice dismissal does not extinguish Mylan’s patent rights or provide Alora with any freedom-to-operate clearance. All eight asserted patents remain in force and Mylan retains the legal right to refile an infringement action. Companies in the ISB injection space should conduct independent FTO analysis and should not rely on this dismissal as IP clearance.
Isosulfan blue (ISB) is a water-soluble blue dye administered by injection to visualise lymphatic vessels during oncological surgery, particularly sentinel lymph node biopsy in breast cancer and melanoma staging. It occupies a narrow but commercially significant niche in surgical oncology. Its specialised use and limited competition make patent protection strategically important, and an eight-patent portfolio over a single injectable product reflects a pharmaceutical lifecycle management approach designed to extend market exclusivity.
Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure allows a plaintiff to dismiss an action without court approval by filing a notice of dismissal before the defendant serves an answer or a motion for summary judgment. In this case, Alora had not yet filed any response, so Mylan was entitled to dismiss as of right. The dismissal took effect automatically upon filing, with no judicial order required. The without-prejudice designation means the same claims can be refiled in the future.
PatSnap Eureka searches patents and litigation data to answer instantly.